UBS raised the firm’s price target on Illumina (ILMN) to $120 from $110 and keeps a Neutral rating on the shares. The firm sees a muted sales growth outlook balanced with outsized margin expansion opportunity following the Q3 results, revised 2025 guidance and 2026 framing, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ILMN:
- Illumina price target raised to $112 from $105 at Canaccord
- Illumina price target raised to $100 from $95 at Barclays
- Illumina Reports Steady Q3 2025 Earnings
- Illumina’s Hold Rating: Balancing Growth Potential with Competitive and Financial Challenges
- Closing Bell Movers: Amazon soars to all-time highs on earnings